Eric Goupil – CEO, Unither, France

Eric Goupil, CEO of Unither Pharmaceuticals, discusses the company’s development strategy moving forward after the completion of a leveraged buyout in 2017. Additionally, Goupil shares the CDMO’s innovation capabilities as a leading player in the Blow-fill-seal (BFS) niche.  
While the continuation of outsourcing by pharmaceutical companies is a trend, I am paying more attention to how the final product market is evolving
Become a PharmaBoardroom Member for free to access this content
Join the 20,000+ pharmaceutical professionals who already subscribe to PharmaBoardroom
Register
Already a member? Sign In
Tags:

Related Interviews

Latest Report